Proven valve tissue
The same proven bovine pericardial leaflet as Edwards surgical valves, treated with the ThermaFix anticalcification process to reduce calcium deposit.
Edwards SAPIEN 3 valve
Setting higher standards for today’s TAVI
Edwards SAPIEN 3 valve
Setting higher standards for today’s TAVI
The defining features of the Edwards SAPIEN 3 valve
Edwards SAPIEN 3 valve is the only transcatheter aortic valve implantation (TAVI) system superior to surgical aortic valve replacement (SAVR) for combined death, stroke and rehospitalisation in aortic stenosis (AS) patients of low-surgical risk.1
Low profile access
Low profile access helps to reduce major vascular complications.
- 2.2% at 30 days post procedure observed across 496 patients in the PARTNER 3 Trial1
Frame design
Low cobalt-chromium frame height and open geometry facilitates future coronary access.2
Outer sealing skirt
The outer sealing skirt virtually eliminates moderate or greater paravalvular leak
- Only 4 of 487 patients assessed at 30 days post TAVI in the PARTNER 3 Trial
Transfemoral delivery system
Edwards SAPIEN 3 valve shares the same optimised, ergonomically designed Edwards COMMANDER and eSheath delivery systems as Edwards SAPIEN 3 Ultra valve.
The Edwards COMMANDER delivery system
Learn more
Aortic and Mitral valve-in-valve procedures
Edwards SAPIEN 3 valve is approved for valve-in-valve procedures in both the aortic and mitral positions, allowing patients at high or greater surgical risk to avoid an additional open-heart procedure.
Aortic | Transfemoral, Transapical, and Transaortic
Mitral | Transseptal, Transapical
3D sizing and delivery system
Edwards SAPIEN 3 valve is available in 4 sizes for maximum flexibility and optimal fitting.
Proven superior to surgery in PARTNER 3 Trial
Edwards SAPIEN 3 TAVI: proven superiority to surgery in low-risk patients1
In the combined end-point of all-cause mortality, stroke, or rehospitalisation at 1 year post-procedure (8.5% for TAVI vs 15.1% for surgery, p=0.001).
Rehospitalisation rates at 1 year.
1% death or disabling stroke at 1 year, approximately 3 times lower than surgery.
PARTNER 3 Trial results enabled Edwards SAPIEN 3 valve to be the first TAVI valve to achieve CE labelling for low-risk severe aortic stenosis (sAS) patients
Edwards SAPIEN 3 valve in PARTNER 3 TrialStay informed with our newsletter
Thank you!
Thank you for signing up to the heartvalves.com newsletter. You will now receive emails on the latest developments and industry insights on heart valve innovation and technology.
References:
1. Mack M, Leon M, Thourani R, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-1705 (plus Supplementary Appendix).
2. Nazif et al. Real-World Experience with the SAPIEN 3 Ultra TAVR: A Propensity Matched Analysis from the United States, TVT Connect 2020.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
PP--EU-3362 v1.0